Clinical trial · Interventional
ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
Feasibility of Blood-based Test for Multi-cancer Early Detection in Asymptomatic Screening Population（ProSight）: a Multi-centre Interventional Study
NCT06790355CI-TRIAL-00125987completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, multi-centre interventional study evaluating the feasibility of blood-based multi-cancer early detection test in asymptomatic screening cohort.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Grastic Cancer | — | UNRESOLVED | — |
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| multi-cancer early detection | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Healthy subjects
- interventionNames
- Device: multi-cancer early detection
Primary outcomes (2)
- measure
- Feasibility of MCED in the intended use setting.
- timeFrame
- From enrollment to the Follow-up at 1 year
- description
- Descriptive statistics will be used to summarize the number of 5 pre-specified cancers diagnosed by MCED.
- measure
- Safety of MCED in the intended use setting.
- timeFrame
- From enrollment to the Follow-up at 1 year
- description
- Descriptive statistics will be used to summarize the time to achieve diagnostic resolution following receipt of a positive MCED test and to assess the extent of testing pursued.
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 74 Years
Show eligibility criteria text
Inclusion Criteria: * 40-74 years old * Able to provide a written informed consent and willing to comply with all parts of the protocol procedures Exclusion Criteria: * With cancer-associated clinical symptoms or suspected of cancer within 30 days prior to screen * Have definite contraindications of cancer screening examination and diagnostic procedures * Unable to comply with the protocol procedures * Personal history of cancer, diagnosed within the 3 years prior to expected enrollment date * Have received or are undergoing curative cancer treatment within three years prior to recruitment. Adjuvant endocrinotherapy for cancer is not an exclusion criterion. * Recipients of anti-tumor therapy within 30 days prior to screen * Pregnancy or lactating women * Recipients of organ transplant or prior bone marrow transplant or stem cell transplant * Recipients of blood transfusion within 7 days prior to screen * With autoimmune diseases * Have an acute infection or inflammation or uncontrolled chronic infection within 14 days prior to blood draw * Unsuitable for this trial determined by the researchers (eg. hemorrhagic diseases)
References
Publications (0)
Data not yet available
No reference posted for this study.